Pfizer news from FierceBioResearcher
NewsCounterpoint: An argument for industry-backed research
Management consultant Dr. David A. Shaywitz has joined with Dr. Dennis A. Ausiello, the physician-in-chief of Massachusetts General Hospital and a director at Pfizer, to deliver a rebuttal to a small Read more...
Translational tech work bridges academia and markets
Northwestern University scientist Richard Silverman's work led to the blockbuster Lyrica, Read more...
Screening method IDs host of HIV drug targets
A team at Harvard Medical School--led by the geneticist Dr. Stephen J. Elledge--has opened up a new slate of drug targets, identifying 273 proteins that aid HIV reproduction in cells. Because the Read more...
Study outlines billions in potential R&D savings
Better standardization of data collection and analysis could save between 25 percent and 48 percent of R&D expenses for each new drug approved by the FDA, according to a new study sponsored by Read more...
Millipore in $1.6B makeover as life sciences supplier
Millipore is expanding on its reputation as a filtration supplier to scientific labs around the globe. Known for purified water and filters, Millipore has leveraged several buyouts to increase its Read more...
New dog therapies help boost Pfizer's top line
Drug researchers at Pfizer have come up with a series of new therapies for dogs. The drug Cerenia, which helps prevent motion sickness in dogs, has now been approved. And researchers recently Read more...
| Press ReleasesPfizerAnnounces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma Pfizer Inc. (PFE) Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma 4/2/2008 NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Read more... Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer SAN JOSE, Calif., Jan 07, 2008 -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, Read more... Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Read more... PRESS RELEASE: Pfizer to Acquire CovX to Extend Biotherapeutics Investment Pfizer to Acquire CovX to Extend Biotherapeutics Investment Acquisition Will Provide Innovative Biotherapeutics Technology Platform and Complementary Product Candidates in Oncology and Diabetes NEW Read more... PRESS RELEASE: Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds NEW YORK & EXTON, Pa. -- Dec 5, 2007 - Pfizer and Adolor Corporation announced Read more... |
Get more Pfizer coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight